ADA 2026 conference reports breakthrough combo drug CagriSema for type‑2 diabetes

At the American Diabetes Association Scientific Sessions 2026 in New Orleans, researchers presented results from the REIMAGINE program evaluating CagriSema, a fixed‑dose combination of cagrilintide (an amylin analogue) and semaglutide (a GLP‑1 agonist). In phase‑3 trials involving about 2,700 participants across 30 countries, the therapy produced greater reductions in HbA1c and body weight than either component alone, with weight loss up to 14 %. Fifty‑seven percent of participants on the highest dose achieved HbA1c ≤ 6.5 % together with at least 10 % weight loss. "L'era dell'amilina è arrivata," said Timothy Garvey.

The conference also highlighted the expanding role of incretin and amylin‑based agents beyond glucose control, including drugs such as survo‑dutide and retatrutide targeting obesity and metabolic liver disease. Continuous glucose monitoring and automated insulin‑delivery systems were discussed as complementary technologies.

Educational material clarified that semaglutide is a synthetic peptide drug, not a food ingredient. It activates GLP‑1 receptors to increase insulin secretion, suppress glucagon, slow gastric emptying and promote satiety. It is available as a weekly subcutaneous injection and, more recently, as a daily oral formulation, and is prescribed for type 2 diabetes and, at specific doses, for chronic weight management.